We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 5 for:    Irritable Bowel Syndrome | Synergy [Lead]
Previous Study | Return to List | Next Study

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (IBS-C)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02387359
First Posted: March 13, 2015
Last Update Posted: October 4, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Synergy Pharmaceuticals Inc.
  Purpose
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.

Condition Intervention Phase
Irritable Bowel Syndrome Characterized by Constipation Drug: Plecanatide Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Resource links provided by NLM:


Further study details as provided by Synergy Pharmaceuticals Inc.:

Primary Outcome Measures:
  • The primary efficacy endpoint is Overall Responder [ Time Frame: 12 weeks ]
    An Overall Responder* is a patient who is a weekly responder (i.e., meets both the abdominal pain intensity and stool frequency responder criteria in the same week) for at least 6 of the 12 treatment weeks.

  • Abdominal Pain Intensity Weekly Responder [ Time Frame: 12 Weeks ]
    An Abdominal Pain Intensity Weekly Responder is defined as a patient who experiences a decrease in the weekly average of worst abdominal pain in the past 24 hours score (measured daily) of at least 30 percent compared with baseline weekly average.

  • Stool Frequency Responder [ Time Frame: 12 Weeks ]
    A Stool Frequency Responder is defined as a patient who experiences an increase of at least one CSBM per week from baseline.


Secondary Outcome Measures:
  • Complete Spontaneous Bowel Movement [ Time Frame: 12 weeks ]
    Change from baseline in CSBM Frequency Rate ( numeric counts )

  • Spontaneous Bowel Movement [ Time Frame: 12 weeks ]
    Change from baseline in SBM Frequency Rate ( numeric counts )

  • Stool Consistency based upon the Bristol Stool Form Scale [ Time Frame: 12 weeks ]
    Change from baseline in stool consistency based upon the Bristol Stool Form Scale (BSFS) Rating 1 to 7

  • Sustained Efficacy Responder [ Time Frame: 12 weeks ]
    Overall Response in the last 4 weeks of the 12 weeks treatment period

  • Time to first SBM and CSBM [ Time Frame: 12 weeks ]
    Time to first SBM and CSBM as measured after first dose of treatment

  • Change and Percent Change from baseline in abdominal pain [ Time Frame: 12 weeks ]
    Change and Percent Change from baseline in abdominal pain as measured with an 11-point (0-10) Numerical Rating Scale

  • Stool Frequency Responder for at least 6 of the 12 treatment weeks [ Time Frame: 12 weeks ]
    Stool Frequency Responder for at least 6 of the 12 treatment weeks ( numeric count of week )

  • Time to first use of Rescue Medication (RM) [ Time Frame: 12 weeks ]
    Time to first use of Rescue Medication (RM) after first dose of treatment

  • Overall Responder for at least 9 of the 12 treatment weeks [ Time Frame: 12 weeks ]
    Overall Responder for at least 9 of the 12 treatment weeks (meets both the abdominal pain intensity and stool frequency responder criteria in the same week )

  • SBMs and CSBMs within 24 hours after first dose of study medication [ Time Frame: 12 weeks ]
    SBMs and CSBMs within 24 hours after first dose of study medication (numeric counts )

  • Symptoms associated with IBS-C [ Time Frame: 12 weeks ]
    Change from baseline in other symptoms associated with IBS-C (abdominal bloating, abdominal discomfort, abdominal cramping, straining with a bowel movement and sensation of incomplete evacuation) all measured on a 11 point scale

  • Patient Global Questionnaires [ Time Frame: 12 weeks ]
    Patient Global Questionnaires (IBS Disease Severity, IBS-Quality of Life, Patient Rating of Relief of IBS Symptoms, Patient Rating of Relief of Abdominal Pain, Treatment Continuation and Treatment Satisfaction Assessments ) all measured on a 5 point scale


Estimated Enrollment: 1050
Study Start Date: December 2014
Study Completion Date: February 2017
Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 3.0 mg plecanatide
Plecanatide 3.0 mg dosed daily for 12 weeks
Drug: Plecanatide
Active Comparator: 6.0 mg plecanatide
Plecanatide 6.0 mg dosed daily for 12 weeks
Drug: Plecanatide
Active Comparator: Matching placebo
Placebo dosed daily for 12 weeks
Drug: Placebo

Detailed Description:

This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.

Screening/Baseline: Patients will undergo an up to 28-day Screening/Baseline period to allow for any necessary diagnostic procedures, allow for required washout of medications and to determine study eligibility. If otherwise eligible based on screening criteria, patients will undergo a 2-week baseline assessment using an electronic diary where they will record daily assessments of bowel movements (BMs), stool consistency (Bristol Stool Form Scale-BSFS), abdominal pain and other IBS-related symptoms. Data from the two-week electronic diary assessment just prior to the randomization visit will be used to confirm IBS-C and study eligibility as well as define the patient's baseline from which change will be determined.

Treatment: Patients who meet all entry criteria will be randomized (1:1:1) to one of three blinded treatment groups on Day 1 of the Treatment period. Patients will take an oral dose of study drug OD for 12 weeks and continue the daily electronic diaries (BMs, rescue medication use, abdominal pain, and other symptoms). During treatment weeks 4, 8, and 12, patients will return to the clinic to undergo safety and efficacy assessments.

Post-Treatment: For 2 weeks after completing dosing, patients will continue to complete daily electronic diaries. Patients will then return to the clinical site for a final follow-up visit during Week 14 following randomization.

The planned duration of participation in this study will be at least 116 days from signing of informed consent through post-treatment or up to approximately 135 days with visit windows considered.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

•Adult patients between the ages of 18 and 85 years (inclusive) with a diagnosis of IBS based on ROME III diagnostic criteria and meeting criteria for diagnosis of the constipation predominant subtype - IBS-C

Exclusion Criteria:

  • Refusal or inability to sign informed consent for the trial
  • Refusal or inability to complete daily Episodic (real-time) BM / RM calls, End of Day daily Calls, and/or complete electronic questionnaires
  • BMI > 35 or < 18
  • Women of child bearing potential who refuse to use an acceptable method of birth control for the duration of the trial
  • Women who are pregnant or lactating
  • Diagnosis of IBS-D or IBS-M
  • Organic or obstructive disease of the small or large intestine
  • Use of laxatives other than the study-supplied rescue medication (Dulcolax®, bisacodyl)
  • Use of a prohibited concomitant medication within the time frame prior to screening outlined in the study protocol for that medication
  • Unstable medical illness
  • Bilirubin > 3X ULN in the absence of a conjugation defect
  • Any laboratory value > 3X ULN unless discussed and approved by the study Medical Monitor
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02387359


  Hide Study Locations
Locations
United States, Alabama
Synergy Research Site
Athens, Alabama, United States
Synergy Research Site
Birmingham, Alabama, United States
Synergy Research Site
Dothan, Alabama, United States
Synergy Research Site
Foley, Alabama, United States
Synergy Research Site
Huntsville, Alabama, United States
Synergy Research Site
Montgomery, Alabama, United States
United States, Arizona
Synergy Research Site
Chandler, Arizona, United States
Synergy Research Site
Glendale, Arizona, United States
Synergy Research Site
Phoenix, Arizona, United States
Synergy Research Site
Tucson, Arizona, United States
United States, Arkansas
Synergy Research Site
Conway, Arkansas, United States
Synergy Research Site
Little Rock, Arkansas, United States
United States, California
Synergy Research Site
Anaheim, California, United States
Synergy Research Site
Artesia, California, United States
Synergy Research Site
Chula Vista, California, United States
Synergy Research Site
Corona, California, United States
Synergy Research Site
Encino, California, United States
Synergy Research Site
Fountain Valley, California, United States
Synergy Research Site
Fresno, California, United States
Synergy Research Site
Garden Grove, California, United States
Synergy Research Site
La Mesa, California, United States
Synergy Research Site
La Mirada, California, United States
Synergy Research Site
Laguna Hills, California, United States
Synergy Research Site
Lancaster, California, United States
Synergy Research Site
North Hollywood, California, United States
Synergy Research Site
Sacramento, California, United States
Synergy Research Site
San Bernardino, California, United States
Synergy Research Site
San Diego, California, United States
Synergy Research Site
Thousand Oaks, California, United States
Synergy Research Site
Upland, California, United States
United States, Colorado
Synergy Research Site
Broomfield, Colorado, United States
Synergy Research Site.
Centennial, Colorado, United States
United States, Connecticut
Synergy Research Site
Bristol, Connecticut, United States
Synergy Research Site
Hamden, Connecticut, United States
United States, Florida
Synergy Research Site
Boynton Beach, Florida, United States
Synergy Research Site
Brandon, Florida, United States
Synergy Research Site
DeLand, Florida, United States
Synergy Research Site
Fort Lauderdale, Florida, United States
Synergy Research Site
Homestead, Florida, United States
Synergy Research Site
Inverness, Florida, United States
Synergy Research Site
Jacksonville, Florida, United States
Synergy Research Site
Miami Lakes, Florida, United States
Synergy Research Site
Miami, Florida, United States
Synergy Research Site
Orlando, Florida, United States
Synergy Research Site
Ormond Beach, Florida, United States
Synergy Research Site
Oviedo, Florida, United States
Synergy Research Site
Pines, Florida, United States
Synergy Research Site
Port Orange, Florida, United States
Synergy Research Site
Saint Petersburg, Florida, United States
Synergy Research Site
Tampa, Florida, United States
United States, Georgia
Synergy Research Site
Atlanta, Georgia, United States
Synergy Research Site
Marietta, Georgia, United States
Synergy Research Site
Norcross, Georgia, United States
Synergy Research Site
Stockbridge, Georgia, United States
United States, Idaho
Synergy Research Site
Idaho Falls, Idaho, United States
United States, Illinois
Synergy Research Site
Chicago, Illinois, United States
Synergy Research Site
Evanston, Illinois, United States
Synergy Research Site
Evergreen Park, Illinois, United States
Synergy Research Site
Rockford, Illinois, United States
United States, Indiana
Synergy Research Site
Evansville, Indiana, United States
United States, Kansas
Synergy Research Site
Augusta, Kansas, United States
Synergy Research Site
Newton, Kansas, United States
Synergy Research Site
Topeka, Kansas, United States
Synergy Research Site
Wichita, Kansas, United States
United States, Louisiana
Synergy Research Site
Baton Rouge, Louisiana, United States
Synergy Research Site
Crowley, Louisiana, United States
Synergy Research Site
Mandeville, Louisiana, United States
Synergy Research Site
Metairie, Louisiana, United States
Synergy Research Site
Monroe, Louisiana, United States
Synergy Research Site
New Orleans, Louisiana, United States
Synergy Research Site
Shreveport, Louisiana, United States
United States, Maryland
Synergy Research Site
Baltimore, Maryland, United States
Synergy Research Site
Hagerstown, Maryland, United States
United States, Massachusetts
Synergy Research Site
Boston, Massachusetts, United States
United States, Michigan
Synergy Research Site
Chesterfield, Michigan, United States
Synergy Research Site
Flint, Michigan, United States
Synergy Research Site
Rochester, Michigan, United States
Synergy Research Site
Wyoming, Michigan, United States
United States, Mississippi
Synergy Research Site.
Jackson, Mississippi, United States
United States, Missouri
Synergy Research Site
Hazelwood, Missouri, United States
United States, Nebraska
Synergy Research Site
Omaha, Nebraska, United States
United States, Nevada
Synergy Research Site
Las Vegas, Nevada, United States
United States, New Jersey
Synergy Research Site
Marlton, New Jersey, United States
United States, New Mexico
Synergy Research Site
Albuquerque, New Mexico, United States
United States, New York
Synergy Research Site
Brooklyn, New York, United States
Synergy Research Site
Great Neck, New York, United States
Synergy Research Site
New Windsor, New York, United States
Synergy Research Site
New York, New York, United States
Synergy Research Site
North Massapequa, New York, United States
United States, North Carolina
Synergy Research Site
Asheboro, North Carolina, United States
Synergy Research Site
Cary, North Carolina, United States
Synergy Research Site
Charlotte, North Carolina, United States
Synergy Research Site
Concord, North Carolina, United States
Synergy Research Site
Davidson, North Carolina, United States
Synergy Research Site
Greensboro, North Carolina, United States
Synergy Research Site
Kinston, North Carolina, United States
Synergy Research Site
Lenoir, North Carolina, United States
Synergy Research Site
Raleigh, North Carolina, United States
Synergy Research Site
Wilmington, North Carolina, United States
Synergy Research Site
Winston-Salem, North Carolina, United States
United States, North Dakota
Synergy Research Site
Fargo, North Dakota, United States
United States, Ohio
Synergy Research Site
Beavercreek, Ohio, United States
Synergy Research Site
Cincinnati, Ohio, United States
Synergy Research Site
Cleveland, Ohio, United States
Synergy Research Site
Englewood, Ohio, United States
Synergy Research Site
Sylvania, Ohio, United States
United States, Oklahoma
Synergy Research Site
Oklahoma City, Oklahoma, United States
Synergy Research Site
Tulsa, Oklahoma, United States
United States, Oregon
Synergy Research Site
Portland, Oregon, United States
United States, Pennsylvania
Synergy Research Site
Levittown, Pennsylvania, United States
Synergy Research Site
Philadelphia, Pennsylvania, United States
Synergy Research Site
Pittsburgh, Pennsylvania, United States
Synergy Research Site
Smithfield, Pennsylvania, United States
Synergy Research Site
Uniontown, Pennsylvania, United States
United States, South Carolina
Synergy Research Site
Columbia, South Carolina, United States
Synergy Research Site
Gaffney, South Carolina, United States
Synergy Research Site.
Greer, South Carolina, United States
Synergy Research Site
North Charleston, South Carolina, United States
United States, South Dakota
Synergy Research Site
Rapid City, South Dakota, United States
United States, Tennessee
Synergy Research Site
Athens, Tennessee, United States
Synergy Research Site
Chattanooga, Tennessee, United States
Synergy Research Site
Memphis, Tennessee, United States
Synergy Research Site.
Nashville, Tennessee, United States
United States, Texas
Synergy Research Site
Arlington, Texas, United States
Synergy Research Site
Austin, Texas, United States
Synergy Research Site
Carrollton, Texas, United States
Synergy Research Site
Dallas, Texas, United States
Synergy Research Site
Houston, Texas, United States
Synergy Research Site
Plano, Texas, United States
Synergy Research Site
San Antonio, Texas, United States
Synergy Research Site
Webster, Texas, United States
United States, Utah
Synergy Research Site
Bountiful, Utah, United States
Synergy Research Site
Ogden, Utah, United States
Synergy Research Site
Saint George, Utah, United States
Synergy Research Site
Sandy City, Utah, United States
United States, Virginia
Synergy Research Site
Alexandria, Virginia, United States
Synergy Research Site
Charlottesville, Virginia, United States
Synergy Research Site
Lynchburg, Virginia, United States
Synergy Research Site
Newport News, Virginia, United States
United States, Washington
Synergy Research Site
Bellevue, Washington, United States
Synergy Research Site
Spokane, Washington, United States
United States, West Virginia
Synergy Research Site
Charleston, West Virginia, United States
Synergy Research Site
Morgantown, West Virginia, United States
United States, Wisconsin
Synergy Research Site
Milwaukee, Wisconsin, United States
Synergy Research Site
Wauwatosa, Wisconsin, United States
Sponsors and Collaborators
Synergy Pharmaceuticals Inc.
Investigators
Study Director: Paul F.C. Eng, PhD Synergy Pharmaceuticals Inc.
  More Information

Responsible Party: Synergy Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT02387359     History of Changes
Other Study ID Numbers: SP304203-04
First Submitted: January 20, 2015
First Posted: March 13, 2015
Last Update Posted: October 4, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Syndrome
Irritable Bowel Syndrome
Intestinal Diseases
Constipation
Disease
Pathologic Processes
Signs and Symptoms, Digestive
Signs and Symptoms
Colonic Diseases, Functional
Colonic Diseases
Gastrointestinal Diseases
Digestive System Diseases
Plecanatide
Gastrointestinal Agents